Sperm DNA Fragmentation Test: Is It Worth Paying For?

Not as a first test, and not because a semen report came back abnormal. Beyond that, the honest answer is that the guidelines genuinely disagree with each other, and you are entitled to know that before you pay.

The newest and most decisive is NICE, whose fertility guideline NG257 was published on 31 March 2026. Its wording is one sentence: “1.17.6 Do not carry out testing for sperm DNA integrity (fragmentation). [2026]” No exceptions, no scenarios. Its committee gave four reasons: the evidence on treating fragmentation showed no convincing benefit, the assays are expensive and can take weeks, the link between elevated fragmentation and subfertility “has not yet been established”, and it is “not clear which type of test and what threshold should be used”.

The other three read differently. The European Association of Urology recommends the test strongly, but only in three named situations: recurrent pregnancy loss after natural conception, failure of assisted reproduction, and unexplained male infertility. The AUA and ASRM split it by indication — do not use it in the initial evaluation of an infertile couple, do include it where there has been recurrent pregnancy loss. The World Health Organization's 2026 infertility guideline does not recommend it either way; it simply makes no male recommendation about it.

Two things follow, and neither of them is “the test is worthless”. First, all four agree it is not a first or routine test, so being offered it alongside a first semen analysis is out of step with every one of them. Second, the strongest recommendation in favour of it — the EAU's — is built on Level 2a observational evidence, which is the same body of work an umbrella review rated critically low quality. A strong recommendation on weak evidence is a real thing, and it is why reasonable bodies end up opposed.

So the useful questions are narrow. Am I in one of the EAU's three situations? And has anyone told me what a high number would change? If the answer to the second is no, the test is spending, not information.

It is the proportion of sperm in that sample whose DNA has breaks in it. Nothing more than that. A semen analysis counts sperm and watches them swim; a fragmentation test looks inside them at whether the genetic material is intact.

Two things follow that are easy to miss. First, the number describes a population, not an individual sperm — a result of 30 means 70 of every 100 sperm in that sample had intact DNA. Second, it is a snapshot of one ejaculate, and the same man produces measurably different samples on different days.

The test is usually offered as the thing conventional semen analysis misses, and that framing has something behind it. The EAU chapter notes that men with unexplained infertility have normal sperm parameters and a normal partner evaluation, and that between one in five and one in three couples fall into unexplained infertility. Looking further is a reasonable instinct. Whether this particular test answers it is the rest of this page.

Because they are not the same test. Four different assays are sold under the same heading, and they do not produce interchangeable numbers.

• SCSA measures how easily sperm DNA comes apart in acid, read on a flow cytometer.
• TUNEL labels the loose ends of broken DNA strands directly.
• The comet assay pulls damaged DNA out of individual sperm in a gel, in either an alkaline or a neutral version.
• The SCD or halosperm test looks at whether chromatin disperses into a halo — no halo means fragmented DNA.

One study ran all five assays in a single cohort of fertile donors and infertile patients and worked out where each one separated the two groups. In that cohort the cut-offs landed at 18.90% for SCSA, 20.05% for TUNEL, 22.75% for the halo test and 45.37% for the alkaline comet assay. The neutral comet assay did not separate the two groups at all and had no predictive power.

The practical consequence is blunt. A percentage means nothing until you know which assay produced it, and a result from one laboratory cannot be compared with a result from another. If your report does not name the assay, that is the first thing to ask for.

Less than the test's marketing implies, and this is the weakest link in the whole chain. A test is only worth doing if the answer changes what you do next.

The umbrella review of this literature is the most useful thing to have read. It screened 49,332 records, included 22 systematic reviews, and rated 18 of them critically low quality with all 22 at high risk of bias. Re-analysing their numbers, the association between fragmentation and live birth was weak in one meta-analysis and non-significant in four. Pregnancy, miscarriage, implantation and fertilisation came out weak or non-significant too. Its conclusion is that it found no convincing or suggestive evidence linking fragmentation to assisted reproduction outcomes.

A separate pooling of 52 studies and 19,930 subjects looked at the test as a predictor rather than an association. Across natural conception, insemination, IVF and ICSI, a high result had low sensitivity, and the summary curves showed poor to moderate discrimination. For miscarriage specifically the authors describe the prediction as poor. Note that this paper opens by saying fragmentation predicts adverse outcomes; its own results say the discrimination is limited. The results are the part to read.

Two things are worth doing on their own merits, whatever the number says: stopping smoking, and having a physical examination for a varicocele. Neither requires the test first.

The most-tested combination raised it. In a trial that randomised 2,370 couples, men taking 5 mg of folic acid with 30 mg of elemental zinc for six months ended with higher DNA fragmentation than men on placebo — 29.7% against 27.2%. Live birth was 404 of 1,185 couples on the supplement and 416 of 1,185 on placebo.

That is one combination, not every antioxidant, and it should not be read as proof that antioxidants damage sperm. What it does establish is that the reasoning behind the sachet — oxidative stress breaks DNA, so antioxidants must mend it — did not survive its largest test. The Cochrane review of 90 randomised trials in 10,303 subfertile men describes the evidence for antioxidants as inconclusive on serious risk of bias.

If a clinic pairs the test with a three-month course of supplements and a repeat test, ask what result would count as a failure, and what happens then. A test that is always followed by the same prescription is not being used as a test.

This is the one intervention aimed specifically at a high result, and it is currently classed as experimental. A pooled analysis of nine studies and more than 536 participants did find higher pregnancy and live birth rates with testicular sperm than with ejaculated sperm in men with high fragmentation. Its authors then state that the availability and quality of the evidence undermine recommendations for clinical practice, and that testicular sperm extraction for ICSI should not be routinely performed.

The EAU guideline reaches the same place from the other direction: it rates this option experimental, at its weakest recommendation strength, pending larger randomised trials.

It also matters that this is a surgical sperm retrieval, with the discomfort, cost and small risks that carries, offered on the strength of observational data. That is a real decision, and it deserves to be presented as one.

About three months for anything you change to reach the sperm being measured. A cycle of sperm production was measured directly in 11 men who drank deuterium-labelled water: labelled sperm appeared in the ejaculate after a mean of 64 days, give or take eight, with a range of 42 to 76 days.

So a repeat fragmentation test three weeks after starting anything is measuring sperm that were already finished when you started. If a retest is worth doing, it is worth doing at about three months, on the same assay, at the same laboratory.

No verified price for a fragmentation test in India was found for this page, so none is quoted here — ask for it in writing before agreeing. What has been measured is the overall burden. Across five tertiary facilities in India, couples seeking care for male-factor infertility spent a median of ₹13,211 out of pocket over a year, with an interquartile range of ₹6,654 to ₹21,521, and 59.4% of all couples in that study met its definition of catastrophic health expenditure.

A separate study of 148 couples undergoing IVF at Indian tertiary centres found that only 5% of 148 had any insurance cover at all, and that drugs and diagnostics made up the majority of what they paid.

That is the context in which an optional diagnostic should be judged. Money spent on a test that will not change the plan is money not available for the cycle itself.

This is the most useful section on the page, because almost everything sold alongside this test sits in it.

• It does not establish that a high result predicts your outcome. Across 52 studies and 19,930 subjects, a high result had low sensitivity and the discrimination was poor to moderate; for miscarriage the authors describe the prediction as poor.
• It does not establish a threshold. Run in one cohort, the five assays gave cut-offs from 18.90% to 45.37%, and no consensus value exists across them. The NICE committee reached the same conclusion in 2026: it is “not clear which type of test and what threshold should be used for defining elevated DNA fragmentation”.
• It does not establish that acting on the result improves live birth. The umbrella review found no convincing or suggestive evidence linking fragmentation to assisted reproduction outcomes, and the one targeted intervention — testicular sperm — is rated experimental.
• It does not establish that antioxidants correct it. The largest randomised test of folic acid with zinc, in 2,370 couples, produced higher fragmentation than placebo and no difference in live birth.
• It does not establish that a normal result clears the male partner. It is one measurement on one sample, and it says nothing about obstruction, hormones, a varicocele or genetics.
• It does not establish anything about the health of a child. No retrieved source on this page links a father's fragmentation result to an outcome in a born child.

Being handed a percentage and no plan is a particular kind of unpleasant, because it converts an uncertainty you were living with into a number that feels like a verdict. It is not one. It is a measurement whose meaning the field is still arguing about.

• How to read your semen analysis report, line by line
• Antioxidants for sperm quality: what the trials found
• Which infections actually harm sperm, and when antibiotics are not the answer
• Sperm epigenetics: what is associated, and why there is no test to buy
• What causes a low sperm count
• How long to abstain before fertility testing